Citadel Advisors
PDLI

Citadel Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

Citadel Advisors’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,957,423
Closed -$6.17M – 11935
2020
Q3 		$6.17M Sell
1,957,423
-535,909
-21% -$1.71M ﹤0.01% 2866
2020
Q2 		$7.26M Sell
2,493,332
-690,346
-22% -$2.18M ﹤0.01% 2588
2020
Q1 		$8.98M Buy
3,183,678
+182,542
+6% +$588K ﹤0.01% 1982
2019
Q4 		$9.74M Buy
3,001,136
+852
+0% +$2.47K ﹤0.01% 2233
2019
Q3 		$6.48M Sell
3,000,284
-7,268
-0.2% -$19.4K ﹤0.01% 2755
2019
Q2 		$9.44M Buy
3,007,552
+500,817
+20% +$1.62M ﹤0.01% 2247
2019
Q1 		$9.32M Sell
2,506,735
-1,734,895
-41% -$5.86M ﹤0.01% 2164
2018
Q4 		$12.3M Sell
4,241,630
-157,181
-4% -$432K 0.01% 1675
2018
Q3 		$11.6M Buy
4,398,811
+850,624
+24% +$2.09M 0.01% 1943
2018
Q2 		$8.3M Buy
3,548,187
+1,948,181
+122% +$5.44M ﹤0.01% 2146
2018
Q1 		$4.7M Buy
+1,600,006
New +$4.37M ﹤0.01% 2532
2017
Q4 		– Sell
-219,860
Closed -$745K – 8848
2017
Q3 		$745K Sell
219,860
-3,439,309
-94% -$9.56M ﹤0.01% 4747
2017
Q2 		$9.04M Sell
3,659,169
-1,810,803
-33% -$4.16M 0.01% 1538
2017
Q1 		$12.4M Buy
5,469,972
+2,445,606
+81% +$5.41M 0.01% 1280
2016
Q4 		$6.41M Buy
3,024,366
+2,956,484
+4,355% +$8.25M 0.01% 1736
2016
Q3 		$228K Buy
67,882
+15,654
+30% +$49.7K ﹤0.01% 6128
2016
Q2 		$164K Buy
52,228
+30,514
+141% +$102K ﹤0.01% 5969
2016
Q1 		$72K Sell
21,714
-537,090
-96% -$1.67M ﹤0.01% 6154
2015
Q4 		$1.98M Buy
558,804
+271,584
+95% +$1.14M ﹤0.01% 2755
2015
Q3 		$1.45M Buy
287,220
+285,098
+13,435% +$1.63M ﹤0.01% 3340
2015
Q2 		$14K Sell
2,122
-571,539
-100% -$3.83M ﹤0.01% 8325
2015
Q1 		$4.04M Buy
573,661
+453,210
+376% +$3.28M ﹤0.01% 2258
2014
Q4 		$928K Buy
120,451
+51,804
+75% +$410K ﹤0.01% 3861
2014
Q3 		$513K Buy
68,647
+56,668
+473% +$526K ﹤0.01% 4583
2014
Q2 		$116K Sell
11,979
-95,282
-89% -$849K ﹤0.01% 6116
2014
Q1 		$892K Sell
107,261
-944,390
-90% -$8.09M ﹤0.01% 3575
2013
Q4 		$8.88M Buy
1,051,651
+42,710
+4% +$360K 0.01% 1284
2013
Q3 		$8.04M Sell
1,008,941
-114,865
-10% -$923K 0.01% 1240
2013
Q2 		$8.68M Buy
+1,123,806
New +$8.76M 0.01% 1164

Other funds holding PDLI

SPC
Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $4.33B AUM 1.35% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Citadel Advisors's PDLI Position: Q4 2020 in Review

Citadel Advisors sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 1,957,423 shares — an estimated $6.17M sold.

Citadel Advisors first reported a position in PDLI in Q2 2013 and held it in 29 quarters. The position peaked at $12.4M in Q1 2017. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

  • Citadel Advisors reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
  • Citadel Advisors sold 1,957,423 PDL BioPharma, Inc. shares in Q4 2020, an estimated $6.17M.
  • Citadel Advisors first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 29 quarters.
  • Citadel Advisors's PDL BioPharma, Inc. position peaked at $12.4M in Q1 2017.
  • 33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on Citadel Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.